The Annals
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 37, No. 2, pp. 274-278. DOI 10.1345/aph.1C314
© 2003 Harvey Whitney Books Company.
This Article
Right arrow Abstract Freely available
Right arrow Résumé Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Backes, J. M
Right arrow Articles by Howard, P. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Backes, J. M
Right arrow Articles by Howard, P. A

OBJETIVO: Repasar la posible asociación entre la estatinas y neuropatía periferal.

FUENTES DE INFORMACIÓN: Se identificó literatura listada en la base de datos de MEDLINE (1984–septiembre 2002) y de IPA (1970–junio 2002). Se incluyeron como términos utilizados para la búsqueda estatinas, neuropatía, e inhibidores de reductasa de HMG-CoA.

SÍNTESIS: Los estudios epidemiológicos y los reportes de casos sugieren un aumento en el riesgo de neuropatía periferal al utilizar las estatinas. La mayoría de los pacientes que desarrollaron neuropatía periferal estaban recibiendo terapia a largo plazo, aunque el tiempo de inicio era bien variable. La mayoría de los casos fueron por lo menos parcialmente reversibles al descontinuar el medicamento. No se han podido identificar factores de riesgo o mecanismos.

CONCLUSIONES: Datos observacionales parecen sugerir una asociación entre el uso crónico de estatinas y un aumento en el riesgo de neuropatía periferal. Sin embargo, el riesgo parece ser pequeño al compararse con los significativos beneficios cardioprotectores.




This article has been cited by other articles:


Home page
 Arch Intern MedHome page
G. Tsivgoulis, K. Spengos, N. Karandreas, M. Panas, A. Kladi, and P. Manta
Presymptomatic neuromuscular disorders disclosed following statin treatment.
Arch Intern Med, July 24, 2006; 166(14): 1519 - 1524.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
T. B. Vaughan and D. S.H. Bell
Statin Neuropathy Masquerading as Diabetic Autoimmune Polyneuropathy
Diabetes Care, August 1, 2005; 28(8): 2082 - 2082.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
A. J.M. Boulton, R. A. Malik, J. C. Arezzo, and J. M. Sosenko
Diabetic Somatic Neuropathies
Diabetes Care, June 1, 2004; 27(6): 1458 - 1486.
[Full Text] [PDF]

Home page
 Toxicol PatholHome page
J. S. MacDonald and M. M. Halleck
The Toxicology of HMG--CoA Reductase Inhibitors: Prediction of Human Risk
Toxicol Pathol, February 1, 2004; 32(2_suppl): 26 - 41.
[Abstract] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Résumé Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Backes, J. M
Right arrow Articles by Howard, P. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Backes, J. M
Right arrow Articles by Howard, P. A

homecopy help contact us subscription past issues search current issue
Copyright © 2003 by Harvey Whitney Books Company.